Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Milestone: CO.26 has reached target accrual

CO.26 - A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies.

CO.26 trial has met its target accrual of 180 patients enrolled and closed to further accrual as of June 28th, 2017. With the great coordination and efforts of our participating site target accrual was reached 8 months ahead of schedule!

Congratulations to CO.26's Top Accruing Investigators!
  • Hagen Kennecke, BCCA - Vancouver Cancer Centre
  • Felix Couture, CHUQ-Pavillon Hotel-Dieu de Quebec, L'Hotel-Dieu de Levis
  • Mohammed Harb, The Moncton Hospital
  • Petr Kavan, The Jewish General Hospital, Montreal
Thank you to all Investigators and site staff who have made the accrual phase of the CO.26 study
such a resounding success! Please ensure your data entry continues to be up-to-date. We will
continue to keep you informed RE trial progress and anticipated analysis date.

If you have additional questions please contact study coordinator Nadine Magoski nmagoski@ctg.queensu.ca